Accelerated Diabetes in Rat Insulin Promoter-Tumor Necrosis Factor-α Transgenic Nonobese Diabetic Mice Lacking Major Histocompatibility Class II Molecules
- 1Department of Immunology, Mayo Clinic, Rochester, Minnesota
- 2Division of Endocrinology, Mayo Clinic, Rochester, Minnesota
- 3Section of Immunobiology and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut
Abstract
The major predisposing genetic component in type 1 diabetes maps to the major histocompatibility complex locus in both mice and humans. To verify the HLA class II association with disease pathogenesis, we adopted the transgenic approach. Expression of HLA-DQ8, the molecule showing the strongest association with human type 1 diabetes, in the diabetes-predisposing milieu of NOD mice in the absence of the endogenous class II molecule I-Ag7 did not render susceptibility to type 1 diabetes. To study if providing a local proinflammatory environment would lead to diabetes in these mice, Aβo.NOD.DQ8 were bred with C57BL/6 mice expressing tumor necrosis factor (TNF)-α in the β-cells of the islets of Langerhans. Surprisingly, although diabetes was evident in the F1 intercross expressing rat insulin promoter (RIP)-TNF, offspring lacking either endogenous or transgenic class II molecules developed accelerated diabetes with high frequency in both sexes. Moreover, expression of any functional class II molecule seemed to confer significant protection from diabetes in this model. Thus, neonatal expression of TNF-α in an islet-specific manner bypassed the requirement of CD4+ T-cells and resulted in diabetes that could be mediated by CD8+ T-cells. We also show for the first time that diabetes in NOD.RIP-TNF mice can occur independent of inheritance of NOD-derived idd1.
Footnotes
-
Address correspondence and reprint requests to Dr. Chella S. David, Department of Immunology, Mayo Clinic, 200 First St., SW, Rochester, MN 55905. E-mail: davic4{at}mayo.edu.
Received for publication 28 June 2002 and accepted in revised form 5 November 2002.
CIITA, class II transactivator; MHC, major histocompatibility complex; RIP, rat insulin promoter; TNF, tumor necrosis factor.
- DIABETES














